Adar Poonawalla
- India
SII applies to Indian authorities for full market authorisation of Covishield
New Delhi: Serum Institute of India (SII) CEO Adar Poonawala on Friday said the vaccines major has applied to Indian authorities for full market authorisation of Covishield, stating supplies of the COVID-19…
- Health
SII vaccine for 3+ kids by mid-2022, says Adar Poonawalla
Mumbai: The Pune-based Serum Institute of India (SII) will launch Covavax — its vaccine for children aged above 3 years — in the next six months, SII CEO Adar Poonawalla said here…
- Bollywood
B-town party: SRK, Kareena, Karisma, Adar Poonawalla share frame
Mumbai: Despite their hectic schedules, a slew of Bollywood stars, including Shah Rukh Khan, Kareena Kapoor Khan, and Karisma Kapoor among others, managed to come together under one roof at a house…
- India
Hopeful of launching Covovax for adults in October this year: Serum CEO
New Delhi: Serum Institute of India CEO Adar Poonawalla on Friday said he is hopeful that Covovax, another COVID-19 vaccine being manufactured by his company in India, will be launched in October for…
- India
Adar Poonawalla sets aside Rs 10 cr to support students travelling abroad
New Delhi: Serum Institute of India CEO and owner Adar Poonawalla on Thursday said that he has set aside Rs 10 crore to support students travelling abroad for studies, as a few countries…
- India
Adar Poonawalla responds to Covishield’s exclusion from EU’s list
New Delhi: Vaccine major Serum Institute of India chief executive officer Adar Poonawalla on Monday said he has taken up the issues faced by Indians who have taken the Covishield jab traveling to…
- India
SII starts production of Covovax, CEO says it has ‘great potential’ for children
In a new move towards ensuring better inoculation, the Serum Institute of India (SII) has started the production of the first batch of the Novavax COVID-19 vaccine in India, dubbed Covovax. Novavax…
- World
SII partner Novavax’s COVID-19 shot 90% effective
Washington: US-based biotechnology company Novavax’s protein-based vaccine has shown overall 90 per cent efficacy against Covid-19, results of Phase-3 trials have shown. The vaccine NVX-CoV2373 is already being locally manufactured by the company’s…
- 1
- 2